MTOR and diabetes mellitus: Numerous studies have demonstrated that rapamycin, a drug that targets mTOR, can inhibit the onset and progression of DN in animal models of diabetes.102, 103, 104 By inhibiting mTOR, rapamycin can alleviate podocyte damage, delay glomerular hypertrophy, and improve the pathological changes associated with DN.